Staff Profile
Professor Nick Reynolds
Professor
- Address: Translational and Clinical Research Institute (Dermatology)
2rd Floor, William Leech Building
Medical School
Newcastle University
NE2 4HH
Current Positions
Professor of Dermatology and Director of Diagnostics, Newcastle University; and Honorary Consultant Dermatologist Newcastle Hospitals NHS Foundation Trust (from 2001);
Roles and Responsibilities
2022-23 President, European Dermatology Forum (EDF)
2021- Secretary General & Vice-President, European Dermatology Forum (EDF)
2021- Lead UK-Irish Atopic eczema Systemic Therapy Register Bioresource (A-STAR Bioresource)
2019- Member Steering Committee, UK-Irish Atopic eczema Systemic Therapy Register (A-STAR)
2019-21 - Chair, Steering Committee, British Association of Dermatologists Biologic Interventions Register (BADBIR)
2018 - Board member European Dermatology Forum (EDF)
2017- 2022 Board member, International Eczema Council
2011 - 2019 - Chair, Research Committee, British Association of Dermatologists Biologic Interventions Register (BADBIR)
2013 - 2017 - Chair, UK Translational Research Network in Dermatology (UK TREND)
2010-2014 Chair, Research Sub-Committee, British Association of Dermatologists (BAD)
2013 - 2014 - President, European Society for Dermatological Research (ESDR)
2008 - 2015 - Board Member, European Society for Dermatological Research (ESDR)
2000-2003 - Chair, British Society for Investigative Dermatology (BSID)
Qualifications
FRCP, Royal College of Physicians, London, 1999
MD University of London, 1995
MBBS University of London, 1983
BSc Hons (Intercalated) University of London, 1980
Post-graduate honours and awards
2023 - Rook Oration, annual meeting British Association of Dermatologists, June 2023
2023- Honorary Membership, European Society for Dermatological Research (ESDR), the highest honour awarded by the Society
2023 - re-selected NIHR Senior Investigator (among the most prominent and prestigious researchers funded by the NIHR and the most outstanding leaders of people-based research within the NIHR research community)
2019 Rudi Cormane Lecture, European Society for Dermatological Research (ESDR)
2019 Eugene M Farber Lecture, Society of Investigative Dermatology (premier psoriasis lecture world-wide)
2019 selected NIHR Senior Investigator (among the most prominent and prestigious researchers funded by the NIHR and the most outstanding leaders of people-based research within the NIHR research community)
2016 Rosetrees Inter-Disciplinary Prize Award (runner up)
2013 Michael Fuell Memorial Lecture, Royal Society of Medicine, London
2008 George Findlay Lecture, Dermatology Society of South Africa
2001-2004 Wellcome Trust Research Leave Fellowship for Clinical Academics
1990-1992 Dowling Travelling Fellowship, British Association of Dermatologists
1990-1992 Josie Bradbury Travelling Fellowship, Psoriasis Association
Previous Positions
- 2016-2019 Director Newcastle MRC/EPSRC Molecular Pathology Node
- 2005-2008 Head of School, Clinical and Laboratory Sciences, Newcastle University
- 2001-2004 Wellcome Trust Research Leave Fellowship for Clinical Academics
- 1995-2001 Senior Lecturer, University of Newcastle upon Tyne and Consultant Dermatologist, Royal Victoria Infirmary, Newcastle upon Tyne
- 1993-1994 Senior Registrar, Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne
- 1990-1992 Research Fellow and Lecturer, Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA
- 1987-1990 Registrar, Department of Dermatology, Bristol Royal Infirmary, Avon
Google Scholar: Click here.
Research Interests
My clinical and research interests are centred on inflammatory skin disease, multiple long term conditions, computational models, artificial intelligence and therapeutics. I am co-lead of Skin and Oral Disease Theme, NIHR Newcastle Biomedical Research Centre (BRC) - one of two NIHR BRC's nationwide with a named theme in Dermatology
On-going projects
• Translational and systems medicine research in dermatology and skin biology
• Precision medicine for psoriasis and atopic eczema; specifically the mechanism of action of anti-psoriatic therapies and predicting clinical outcomes of biologics (PSORT; BADBIR) and ultraviolet B (UVB, Rosetrees Interdisciplinary Prize Award and follow up funding)
• Clinical trials, molecular genetics and disease models of atopic eczema
• Biologics, UV and wound healing signalling responses
• AI and machine learning approaches to transcriptomic and population data
• Interplay between Multiple Long Term Conditions and Polypharmacy (AI-MULTIPLY and NIHR Newcastle Patient Safety Research Collaboration)(PSRC)
My research group is interested in applying novel approaches to understanding inflammatory skin disease (specifically psoriasis and atopic eczema) and their associated co-morbidities. We have a particular interest in gaining insights into disease mechanisms and the pathways involved in clearing psoriasis. l co-lead a workstream in PSORT focused on immune biomarkers in skin and blood, with a particular focus on transcriptomic analysis during the the early phases of biologic therapy.
The Psoriasis Stratification to Optimise Relevant Therapy (PSORT) consortium is a unique partnership between five UK universities: Manchester, Newcastle, King’s College London, Queen Mary and Liverpool, 10 pharmaceutical and diagnostics companies and the Psoriasis Association and NHS partners representing patients. This experimental medicine project has identified clinical, pharmacological, immune, and molecular biomarkers of clinical response of psoriasis to biologic therapy.
We also study the mechanism of action of anti-psoriatic therapies including UVB and biologics (supported by the Rosetrees Trust (co-lead with Dr Paolo Zuliani, School of Computing; now Università di Roma "La Sapienza" Rome, Italy) and Newcastle's NIHR Biomedical Research Centre), as we think this may provide important insights into disease pathogenesis and lead to the identification of new therapeutic targets. We are interested in understanding the regulation of diverse cellular responses induced by UVR. These studies are supported by important collaborations with Dr Sophie Weatherhead, Dermatology RVI. On-going studies focus on the induction of apoptosis, circadian rhythm, redox, mitochondrial and and atherosclerotic signalling by UVR in the clearance of psoriatic plaques.
We have conducted important investigator-led clinical trials in atopic eczema (e.g. REF 2014 impact case) and have contributed to increased understanding of the molecular genetics of atopic eczema. We have set up a filaggrin-knockdown skin equivalent model of atopic eczema and identified key downstream targets of filaggrin including kallikrein 7 and cyclophilin A using a proteomic approach (with Stiefel/GSK).
Another area of focus is keratinocyte cell signalling, particularly in response to environmental insults such as ultraviolet radiation, wounding (in collaboration with Prof Jeremy Lakey, through a EPSRC/BBSRC Innovate UK project).
Between 2016 and 2019, I was Director of the Newcastle MRC Molecular Pathology Node, one of six units established across the UK to bring researchers, clinicians and industry together to develop molecular diagnostic tools for precision medicine. A key aim was to reinvigorate diagnostic research and development within the NHS, thereby enhancing training and building capacity. We established a Proximity research laboratory within the NHS pathology department to develop tissue biomarkers of clinical response and image these multi-dimentionally. I also lead the stratified medicine theme of NIHR Newcastle In Vitro Diagnostics Co-operative.
Our on-going collaborations with computer scientists and informaticians led to the recent award (2022) of a NIHR AiM collaboration grant for Multiple Long-Term Conditions - (AI-MULTIPLY)(which I co-lead with Professor Mike Barns, Queen Mary College, London and also involves Professor Paolo Missier, School of Computing). This consortium links the North East of England and East London, areas of social deprivation with contrasting ethnic diversity and is focused on understanding the interrelationship between Polypharmacy, Multiple Long-Term Conditions and Intersectional Factors. Additionally, Newcastle was recently awarded a NIHR Newcastle Patient Safety Research Collaboration (PSRC, led by Professor Andy Husband), commencing March 2023. Mike Barnes and I are leading a work-stream on Artificial intelligence and data science in Multiple Long-Term Conditions that involves collaborations with clinical colleagues including Dr Philip Hampton.
Research Group Members:
- Dr Graham Smith, PSORT post-doctoral systems biologist and bioinformatician
- John Casement, informatics analyst, NIHR AiM AI-MULTIPLY
- Dr Wasim Iqbal, informatics analyst, NIHR AiM AI-MULTIPLY
- Dr Rebeen Hamad, post-doctoral Research Associate and informatics analyst, NIHR AiM AI-MULTIPLY (with Professor Paolo Missier)
- Michelle Miller, NIHR AiM AI-MULTIPLY, project manager
- Dr Tom Ewen, A-Star bio project manager
- Jenny Lumley, NIHR BRC and A-Star bio Research Technician
- Dr Henry Graham, MRC Clinical Training Fellow
- Dr Amaani Hussain, MRC Clinical Training Fellow
- Dr Ashley Rider, NIHR BRC post-doctoral Research Associate
- Ayesha Sahar, NIHR PSRC Research Assistant
- Jessie Nie, PhD student (Newcastle University and Chinese government scholarship program)
- Liyuan Zhu, NIHR PSRC PhD student
Postgraduate Supervision
Yes
Funding
- MRC PSORT
- NIHR Newcastle Biomedical Research Centre
- NIHR AiM Collaboration grant for Multiple Long-Term Conditions - AI-MULTIPLY
- NIHR Newcastle In Vitro Diagnostics Co-operative
- NIHR Newcastle Patient Safety Research Collaboration (PSRC)
- Psoriasis Association
- EPSRC/BBSRC Innovate UK
- Rosetrees Foundation
- UCB
We place a strong emphasis on undergraduate teaching and postgraduate training and we have an outstanding track record in training future leaders in the field. We run an active weekly programme within dermatology (clinical and basic science journal clubs, research in progress meetings) and play a key role in the MRes in Medical and Molecular Biosciences.
Many of our clinical trainees pursue higher research degrees funded through external nationally funded fellowships (Wellcome, MRC, Action Medical Research, British Skin foundation) and our PhD students have secured fellowships (European Commission), post-doctoral positions (eg Settembre lab, TIGEM, Pozzuoli, Italy; Khavari lab, Stanford; Buck Institute, San Francisco; NIH, Bethesda; University of Chicago) and faculty positions (UNIVERSITY OF NAMUR, Belgium).
Since 2006/2007, we have been one of a limited number of departments in England and Wales to be regularly awarded academic clinical fellowships in dermatology. Currently, four out of the 14 academic clinical fellows from all medical specialties in the North East are in Dermatology.
Since 2008, three of our clinical trainees have gone on to secure prestigious Wellcome Intermediate Fellowships, one in Dundee and two in Newcastle. Two of these investigators were recently awarded Senior Wellcome Fellowships in Clinical Science (one in Dundee and one in Newcastle).
Postgraduate Student Supervision - Current primary supervisor
- Dr Henry Graham, MRC Clinical Training Fellow
- Dr Amaani Hussain, MRC Clinical Training Fellow
- Dr Ashley Rider, NIHR BRC post-doctoral Research Associate
- Jessie Nie, PhD student (Newcastle University and Chinese government scholarship program)
- Liyuan Zhu, NIHR PSRC PhD student
Postgraduate Student Supervision - Completed
- Ashley Rider (PhD), 2023*
- Martina Elias (PhD), 2017*
- Emma Woodward PhD, 2017*
- Keith Wu (PhD), 2015*
- Laura Hudson PhD, 2014*
- Aparna Sinha MD, 2014*
- Darren Johnson PhD, 2013*
- Nicola Fullard PhD, 2013
- Alison Forrester PhD, 2012*
- Sophie Weatherhead PhD, 2011*
- Shanji Anthony MPhil, 2009*
- Sarah Milner PhD, 2009*
- Baba Taal PhD, 2009*
- Sara Brown MD with commendation, 2008
- Muzz Haniffa PhD, 2008
- Ross Flockhart PhD, 2007*
- Simon Meggitt MD with distinction, 2006*
- Philip Hampton PhD, 2006*
- Sandy McBride MD with commendation, 2002*
- Wael Al-Daraji MD, 2002*
- Paula Fearon PhD, 2002*
*Primary supervisor
RECENT INVITED LECTURES AT NATIONAL/INTERNATIONAL CONFERENCES
2023
- Advanced Euroderm Excellence Virtual Conference, Atopic eczema: from pathophysiology to therapeutics, Vienna, November 2023
- 32nd CONGRESS, EADV, Big Data and Dermatology, What patient registries have taught us, October 2023
- Finnish Dermatology Society Meeting Towards precision medicine for inflammatory skin disease, September 2023
- Rook Oration, annual meeting British Association of Dermatologists, A systems medicine and AI approach for inflammatory skin disease: future perspectives, June 2023
- NIHR Aim consortium meeting, Using artificial intelligence (AI) to characterise the dynamic inter-relationships between multiple long-term conditions and polypharmacy across diverse UK populations and inform health care pathways, May 2023
2022
- aEuroderm Excellence Virtual Conference: Introduction about the Advanced Euroderm Excellence and the European Dermatology Forum. Virtual Meeting. January 2022
- Inaugural UK MLTC Symposium. Virtual Meeting. MLTC, polypharmacy, and artificial intelligence: introducing AI MULTIPLY Using artificial intelligence (AI) to characterise the dynamic inter-relationships between multiple long-term conditions and polypharmacy across diverse UK populations and inform health care pathways. March 2022
- Joint meeting British Association of Dermatologists and the Royal College of Physicians. Liverpool. The Importance of Dermatology Research and its Impact on Patient Care. May 2022
- Janssen GRAPPA UK Workshop Meeting. Leeds Patient management in PsO and PsA. March 2022
- International Psoriasis Council, Society of Investigative Dermatology. Portland, USA May 2022 Real -World Data and Psoriasis: World Data and Psoriasis: World Data and Psoriasis: World Data and Psoriasis. A European Perspective
- Mass General Dermatology/Harvard Grand Rounds Lecture. Computational modelling, systems biology and AI for psoriasis: future perspectives. Virtual. July 2022
2021
- International Psoriasis Council: Global Webinar Series: What registries have taught us on stratification in treatment
- Diagnostic North East, Virtual Conference: closing remarks. Virtual Meeting
- 30th CONGRESS, EADV VIRTUAL: The promise of personalized medicine;
- ESDR International Eczema Council: chair Human Models of Atopic Dermatitis symposium and introductory remarks. Virtual Meeting
- BSID: Developments in precision medicine: insights from the PSORT programme
- International Psoriasis Council, Global Webinar Series, What registries have taught us on stratification in treatment. Virtual Meeting
- North of England Dermatological Society and Scottish Dermatological Society meeting: Precision medicine in dermatology – hype or reality?; Virtual Meeting
- IMID bio-UK: PSORT Insights from analyses across skin and blood; Virtual Meeting
- NIHR IMID Bioresource: PSORT Towards scalable biomarkers and precision medicine. Virtual Meeting
2020
- EAACI Digital Conference: “Human and computational models of immune mediated inflammatory skin disease:challenges, insights and perspectives”
- 29th Congress, EADV Virtual: “Biologics in dermatology – Present and future – The promise of personalised medicine”
- 35th Annual Meeting of the Japanese Society for Psoriasis Research “BADBIR and PSORT programs: Personalised medicine and Biomarkers”
2019
- Scottish Dermatological Society: “Therapies and therapeutic approaches for atopic eczema”
- BAD StR Training Event, London: "What’s new in atopic dermatitis?"
- EADV 2019 Meeting, Madrid, Spain, Training and Educational Forum: “Atopic dermatitis: Pathophysiology”
- ESDR, Bordeaux. France: Rudi Cormane Lecture: "A systems biology and computational modelling approach to inflammatory skin disease" (https://www.youtube.com/watch?v=eICut0J1-go)
- Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Annual Meeting and Trainee Symposium; Paris, France: "Towards precision medicine in psoriasis: update from BADBIR and PSORT programs"
- British Photodermatology Group, BAD Annual Meeting, Liverpool: "Phototherapy for atopic eczema"
- World Congress in Dermatology, Milan, Italy: "Therapeutic stratification of monoclonal antibodies for psoriasis"
- Society of Investigative Dermatology, Chicago, USA: Eugene M Farber Lecture: "Towards precision therapeutics: a systems approach to understanding psoriasis plaque resolution and endotype analysis"
2018
- Psoriasis Association, 50th Anniversary; Psoriasis: translating innovation into personalised care: “Systems biology and computational modelling for psoriasis: future perspectives”
- Euroderm Excellence, Nice: Atopic eczema The current treatment landscape
- EADV, Paris; Training and Educational Forum: Atopic dermatitis: Epidemiology and Pathophysiology
- ESDR-EADV Summer Research Course, Naples: Transcriptomic analysis of psoriasis following UVB and biologic therapy
- Bionow Precision Medicine Conference, Leeds: Taking biomarker discovery through to implementation
- Dubai Academy of Dermatology Meeting: Navigating the psoriasis armamentarium in 2018, an holistic approach
- Dubai Academy of Dermatology Meeting: P4 medicine for psoriasis and inflammatory skin disease
2017
- Immune Mediated Inflammatory Diseases (IMID) Summit: "Using real world evidence to inform best-practice: psoriasis"
- Euroderm: "Psoriasis, navigating the treatment armamentarium"
- European Association for Dermato-Venereology (EADV) annual meeting: "Atopic eczema clinical features and treatments"
2016
- RCP Advanced Medicine Course, Abu Dhabi: Translation of Clinical Research into Personalised Medicine
- British Society for Rheumatology, Glasgow: “Newer therapeutic agents for psoriasis: a dermatological perspective
- Psoriasis Association AGM, Northampton: “Psoriasis Stratification to Optimise Relevant Therapy (PSORT)”.
- European Association for Dermato-Venereology (EADV) Fostering Course, Rotterdam, The Netherlands: “How to run a clinical trial”.
- British Association of Dermatologists (BAD) Annual meeting, Birmingham Derm School: Translational Dermatology
2015
- BSID, Southampton, UK: UK TREND - an opportunity for research
- World Congress of Dermatology, Vancouver, Canada: A systems biology approach to understanding the mechanism of action of UVB phototherapy in psoriasis
- World Congress of Dermatology, Vancouver, Canada: Systems dermatology: insights into epidermal remodeling in psoriasis
- BAD Annual Meeting, Manchester, UK: Research across the academic industrial interface
- BAD Annual Meeting, Manchester, UK: Engaging with UK Translational Research Network in Dermatology
- European Dermatoepidemiology Network, ESDR, Rotterdam, Netherlands: Personalised Medicine for Skin Diseases
- EADV Annual Meeting, Copenhagen, Denmark: A critical appraisal of biologics for psoriasis
- Real World Evidence Conference (Janssen), London, UK: BADBIR and PSORT: a pharmacovigilance registry leading onto a stratified medicine initiative
- ‘Allergy & the Skin’ Study Day, London, UK How should we manage patients with difficult atopic eczema
2014
- EADV Annual Meeting, Amsterdam, The Netherlands: “Personalised medicine for inflammatory skin disease”
- BAD Annual Meeting, Glasgow, UK: “Physiology and importance of IL-17 in the pathogenesis of psoriasis”
- ESDR/EADV Summer Research School, Helsinki, Finland: “Cutaneous transcriptomics”
- RCP of Edinburgh Symposium on Dermatology: “How should we manage patients with difficult eczema?”
- KSID, Seoul, South Korea: “Mechanistic insight into epidermal remodelling in psoriasis: a systems biology approach”
2013
- Leo Research Foundation Prize Award Ceremony, Copenhagen, Denmark: “The dynamic platform of translational research: from bench to bedside and back again”
- ESDR Future Leaders Academy, Florence, Italy, A journey through Translation
- Medicine and me symposium, RSM, London: “Key advances in psoriasis research” http://www.rsmvideos.com/videoPlayer/?vid=436&class=videoThumb
- EADV meeting, Istanbul: “Keratinocyte apoptosis in remodeling and clearance of psoriatic plaques” and “Efficacy of phototherapy in childhood and adult atopic eczema”
- BAD Annual Meeting, Liverpool: “Future psoriasis therapy beyond TNF-a blockade” and “Systemic treatment for severe adult atopic dermatitis”
- Psoriasis International Network Congress, Paris: “Resistant palmoplantar pustulosis” and “The impact and management of psoriasis in pregnancy”
- Irish Association of Dermatologists Meeting, Belfast
- RSM Michael Fuell Memorial Lecture, London: “Systems biology in dermatology: mechanistic insight into epidermal remodelling in psoriasis”
-
Articles
- Ewen T, Husain A, Stefanos N, Barrett P, Jones C, Ness T, Long A, Horswell S, Bosomworth H, Lowenstein J, Richardson G, Swan D, McConnell A, Rose A, Andrew T, Reynolds N, Malvehy J, Carrera C, Alos L, Mailer S, Helm T, Ding L, Bogner P, Podlipnik S, Puig S, McArthur GA, Paragh G, Labus M, Sloan P, Armstrong JL, Lovat PE. Validation of epidermal AMBRA1 and loricrin (AMBLor) as a prognostic biomarker for nonulcerated American Joint Committee on Cancer stage I/II cutaneous melanoma. British Journal of Dermatology 2024, 190(4), 549-558.
- Mason KJ, Alabas OA, Dand N, Warren RB, Reynolds NJ, Barker JNWN, Yiu ZZN, Smith CH, Griffiths CEM. Characteristics of ‘super responders’ and ‘super nonresponders’ to first biologic monotherapy for psoriasis: a nested case–control study. British Journal of Dermatology 2024, 190(3), 441-444.
- Hussain AB, Singleton G, Ball S, Weatherhead SC, Reynolds NJ, Hampton PJ. Adopting a personalized approach to blood monitoring in patients with psoriasis prescribed biologic therapy: a retrospective single-centre review of real-world data. Clinical and Experimental Dermatology 2024, 49(2), 181-183.
- Tsakok T, Saklatvala J, Rispens T, Loeff FC, de Vries A, Allen MH, Barbosa IA, Baudry D, Dasandi T, Duckworth M, Meynell F, Russell A, Chapman A, McBride S, McKenna K, Perera G, Ramsay H, Ramesh R, Sands K, Shipman A, Burden AD, Griffiths CE, Reynolds NJ, Warren RB, Mahil S, Barker J, Dand N, Smith C, Simpson MA. Development of antidrug antibodies against adalimumab maps to variation within the HLA-DR peptide-binding groove. JCI insight 2023, 8(4), e156643.
- Niaouris A, Hernandez-Cordero A, Haddad S, Hassi NK, Benzian-Olsson N, Bugarin Diz C, Burden AD, Cooper HL, Griffiths CEM, Parslew R, Pink AE, Reynolds NJ, Wahie S, Warren RB, Wright A, Simpson M, Baum P, Visvanathan S, Barker JN, Smith CH, Capon F, Abraham T, Ali M, August S, Baudry D, Becher G, Bewley A, Cornelius V, Dunnill G, Ferguson A, Ghaffar S, Ingram J, Kavakleiva S, Kelly S, Khorshid M, Lachmann H, Ladoyanni E, McAteer H, McKenna J, Meynell F, Levell N, Patel P, Pushparajah A, Sinclair C, Wachsmuth R, Wilson R. Damaging Alleles Affecting Multiple CARD14 Domains Are Associated with Palmoplantar Pustulosis. Journal of Investigative Dermatology 2023, 143(3), 504-508.e5.
- Bosma AL, Ouwerkerk W, Heidema MJ, Prieto-Merino D, Ardern-Jones MR, Beattie P, Brown SJ, Ingram JR, Irvine AD, Ogg G, Patel P, Reynolds NJ, Hearn RMR, Wan M, Warren RB, Woolf RT, Hyseni AM, Gerbens LAA, Spuls PI, Flohr C, Middelkamp-Hup MA. Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types. JAAD International 2023, 10, 14-24.
- Ding Y, Dhawan G, Jones C, Ness T, Nichols E, Krasnogor N, Reynolds NJ. An open source pipeline for quantitative immunohistochemistry image analysis of inflammatory skin disease using artificial intelligence. Journal of the European Academy of Dermatology and Venereology 2023, 37(3), 605-614.
- Shmarov F, Smith GR, Weatherhead SC, Reynolds NJ, Zuliani P. Individualised computational modelling of immune mediated disease onset, flare and clearance in psoriasis. PLoS Computational Biology 2022, 18(9), e1010267.
- Yiu ZZN, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, Warren RB, Griffiths CEM. Drug Survival Associated with Effectiveness and Safety of Treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis. JAMA Dermatology 2022, 158(10), 1131-1141.
- Douroudis K, Ramessur R, Barbosa IA, Baudry D, Duckworth M, Angit C, Capon F, Chung R, Curtis CJ, Di Meglio P, Goulding JMR, Griffiths CEM, Lee SH, Mahil SK, Parslew R, Reynolds NJ, Shipman AR, Warren RB, Yiu ZZN, Simpson MA, Barker JN, Dand N, Smith CH, Evans I, Murphy R, McPherson T, Kleyn E, Laws P, Becher G, Bewley A, Rashid A, Alabas O, Morrison S, Ahmed S, Pearson E, Richards J, Mackenzie T, Kirby B, Burden D, Lawson L, McElhone K, Ormerod A, Owen C, Aldoori N, Ali M, Anstey A, Antony F, Archer C, August S, Balasubramaniam P, Baxter K, Bonsall A, Brown V, Burova K, Butt A, Caswell M, Cliff S, Costache M, Darne S, Davies E, DeGiovanni C, Desai T, DeSilva B, Diba V, Domanne E, Dymond H, Fahy C, Ferguson L, Gkini M-A, Godwin A, Hammonds F, Johnson S, Joseph T, Kalavala M, Khorshid M, Labinoti L, Lawson N, Layton A, Lees T, Levell N, Lewis H, Lyon C, McBride S, McCormack S, McKenna K, Mellor S, Norris P, Popli U, Perera G, Ponnambath N, Ramsay H, Ranasinghe A, Reeken S, Rose R, Rotarescu R, Salvary I, Sands K, Sinha T, Stefanescu S, Sundararaj K, Taghipour K, Taylor M, Thomson M, Topliffe J, Verdolini R, Wachsmuth R, Wade M, Wahie S, Walsh S, Walton S, Wilcox L, Wright A. Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000 People with Psoriasis. Journal of Investigative Dermatology 2022, 142(6), 1617-1628.e10.
- Cro S, Cornelius VR, Pink AE, Wilson R, Pushpa-Rajah A, Patel P, Abdul-Wahab A, August S, Azad J, Becher G, Chapman A, Dunnil G, Ferguson AD, Fogo A, Ghaffar SA, Ingram JR, Kavakleiva S, Ladoyanni E, Leman JA, Macbeth AE, Makrygeoegou A, Parslew R, Ryan AJ, Sharma A, Shipman AR, Sinclair C, Wachsmuth R, Woolf RT, Wright A, McAteer H, Barker JNWN, Burden AD, Griffiths CEM, Reynolds NJ, Warren RB, Lachmann HJ, Capon F, Smith CH. Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT). British Journal of Dermatology 2022, 186(2), 245-256.
- Addison R, Weatherhead SC, Pawitri A, Smith GR, Rider A, Grantham HJ, Cockell SJ, Reynolds NJ. Therapeutic wavelengths of ultraviolet B radiation activate apoptotic, circadian rhythm, redox signalling and key canonical pathways in psoriatic epidermis. Redox Biology 2021, 41, 101924.
- Watson N, Wilson N, Shmarov F, Zuliani P, Reynolds NJ, Weatherhead SC. The use of psoriasis biomarkers, including trajectory of clinical response, to predict clearance and remission duration to UVB phototherapy. Journal of the European Academy of Dermatology and Venereology 2021, 35(11), 2250-2258.
- Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB. Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study from the British Association of Dermatologists Biologics and Immunomodulators Register. JAMA Dermatology 2021, 157(1), 66-73.
- Andres-Ejarque R, Ale HB, Grys K, Tosi I, Solanky S, Ainali C, Catak Z, Sreeneebus H, Saklatvala J, Dand N, de Rinaldis E, Chapman A, Nestle FO, Barnes MR, Warren RB, Reynolds NJ, Griffiths CEM, Barker JN, Smith CH, Di Meglio P. Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis. Nature Communications 2021, 12(1), 4741.
- Hudson L, Begg M, Wright B, Cheek TR, Jahoda CAB, Reynolds NJ. Dominant effect of gap junction communication in wound-induced calcium wave, NFAT activation and wound closure in keratinocytes. Journal of Cellular Physiology 2021, 236(12), 8171-8183.
- Reynolds G, Vegh P, Fletcher J, Poyner EFM, Stephenson E, Goh I, Botting RA, Huang N, Olabi B, Dubois A, Dixon D, Green K, Maunder D, Engelbert J, Efremova M, Polański K, Jardine L, Jones C, Ness T, Horsfall D, McGrath J, Carey C, Popescu D-M, Webb S, Wang X-N, Sayer B, Park J-E, Negri VA, Belokhvostova D, Lynch MD, McDonald D, Filby A, Hagai T, Meyer KB, Husain A, Coxhead J, Vento-Tormo R, Behjati S, Lisgo S, Villani A-C, Bacardit J, Jones PH, O'Toole EA, Ogg GS, Rajan N, Reynolds NJ, Teichmann SA, Watt FM, Haniffa M. Developmental cell programs are co-opted in inflammatory skin disease. Science 2021, 371(6527), eaba6500.
- Geifman N, Azadbakht N, Zeng J, Wilkinson T, Dand N, Buchan I, Stocken D, Di Meglio P, Warren RB, Barker JN, Reynolds NJ, Barnes MR, Smith CH, Griffiths CEM, Peek N. Defining trajectories of response in patients with psoriasis treated with biologic therapies. British Journal of Dermatology 2021, 185(4), 825-835.
- Pan S, Tsakok T, Dand N, Lonsdale DO, Loeff FC, Bloem K, de Vries A, Baudry D, Duckworth M, Mahil S, Pushpa-Rajah A, Russell A, Alsharqi A, Becher G, Murphy R, Wahie S, Wright A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, David Burden A, Rispens T, Standing JF, Smith CH, Benham M, Evans I, Hussain S, Kirby B, Lawson L, Mason K, McElhone K, Ormerod A, Owen C, Barnes MR, Di Meglio P, Emsley R, Evans A, Payne K. Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study. Clinical and Translational Science 2020, 13(2), 400-409.
- Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsley R, Marsden A, Evans I, Warren RB, Stocken D, Barker JN, Burden AD, Smith CH. Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). British Journal of Dermatology 2020, 182(5), 1158-1166.
- Ritchlin CT, Pennington SR, Reynolds NJ, FitzGerald O. Moving Toward Precision Medicine in Psoriasis and Psoriatic Arthritis. Journal of Rheumatology 2020, 96(Supplement), 19-24.
- Richardson A, Powell AK, Sexton DW, Parsons JL, Reynolds NJ, Ross K. microRNA-184 is induced by store-operated calcium entry and regulates early keratinocyte differentiation. Journal of Cellular Physiology 2020, 235(10), 6854-6861.
- Vergnano M, Mockenhaupt M, Benzian-Olsson N, Paulmann M, Grys K, Mahil SK, Chaloner C, Barbosa IA, August S, Burden AD, Choon S-E, Cooper H, Navarini AA, Reynolds NJ, Wahie S, Warren RB, Wright A, Abraham T, Ali M, Baudry D, Bewley A, Ingram J, Kelly S, Korshid M, Ladoyanni E, McKenna J, Meynell F, Parslew R, Patel P, Pushparajah A, Reynolds N, Smith C, Warren R, Huffmeier U, Baum P, Visvanathan S, Barker JN, Smith CH, Capon F. Loss-of-Function Myeloperoxidase Mutations Are Associated with Increased Neutrophil Counts and Pustular Skin Disease. American Journal of Human Genetics 2020, 107(3), 539-543.
- Ellis R, Tang D, Nasr B, ClinRes M, Greenwood A, McConnell A, Anagnostou ME, Elias M, Verykiou S, Bajwa D, Ewen T, Reynolds NJ, Barrett P, Carling E, Watson G, Armstrong J, Allen AJ, Horswell S, Labus M, Lovat PE. Epidermal autophagy and beclin 1 regulator 1 and loricrin: a paradigm shift in the prognostication and stratification of the American Joint Committee on Cancer stage I melanomas. British Journal of Dermatology 2020, 182(1), 156-165.
- Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB, the BADBIR Study Group. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology 2020, 183(2), 294-302.
- Loeff FC, Tsakok T, Dijk L, Hart MH, Duckworth M, Baudry D, Russell A, Dand N, van Leeuwen A, Griffiths CEM, Reynolds NJ, Barker J, Burden AD, Warren RB, de Vries A, Bloem K, Wolbink GJ, Smith CH, Rispens T, Benham M, Burden D, Evans I, Griffiths C, Hussain S, Kirby B, Lawson L, Mason K, McElhone K, Murphy R, Ormerod A, Owen C, Reynolds N, Smith C, Warren R, Barker JNWN, Barnes MR, DiMeglio P, Emsley R, Evans A, Payne K, Stocken D. Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study. Journal of Investigative Dermatology 2020, 140(11), 2129-2137.
- Benzian-Olsson N, Dand N, Chaloner C, Bata-Csorgo Z, Borroni R, Burden AD, Cooper HL, Cornelius V, Cro S, Dasandi T, Griffiths CEM, Kingo K, Koks S, Lachmann H, McAteer H, Meynell F, Mrowietz U, Parslew R, Patel P, Pink AE, Reynolds NJ, Tanew A, Torz K, Trattner H, Wahie S, Warren RB, Wright A, Barker JN, Navarini AA, Smith CH, Capon F. Association of Clinical and Demographic Factors with the Severity of Palmoplantar Pustulosis. JAMA Dermatology 2020, 156(11), 216-1222.
- Watson N, Wu K, Farr P, Reynolds NJ, Hampton PJ. Ustekinumab exposure during conception and pregnancy in patients with chronic plaque psoriasis: a case series of 10 pregnancies. British Journal of Dermatology 2019, 180(1), 195-196.
- Yiu ZZN, Ashcroft DM, Evans I, McElhone K, Lunt M, Smith CH, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB, BADBIR Study Group. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). British Journal of Dermatology 2019, 180(2), 329-337.
- Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, Burden AD, Reynolds NJ, Stocken D, Emsley R, Griffiths CEM, Smith C. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. British Journal of Dermatology 2019, 180(5), 1069-1076.
- Wilkinson N, Tsakok T, Dand N, Bloem K, Duckworth M, Baudry D, Pushpa-Rajah A, Griffiths CEM, Reynolds N, Barker J, Warren RB, Burden AD, Rispens T, Stocken D, Smith C, BSTOP study group, PSORT consortium. Defining the therapeutic range for adalimumab and predicting response in psoriasis: amulticenter prospective observational cohort study. Journal of Investigative Dermatology 2019, 139(1), 115-123.
- Twelves S, Mostafa A, Dand N, Burri E, Farkas K, Wilson R, Cooper HL, Irvine AD, Oon HH, Kingo K, Koks S, Mrowietz U, Puig L, Reynolds N, Tan EST, Tanew A, Torz K, Trattner H, Valentine M, Wahie S, Warren RB, Wright A, Bata-Csorgo Z, Szell M, Griffiths CEM, Burden AD, Choon SE, Smith CH, Barker JN, Navarini AA, Capon F. Clinical and genetic differences between pustular psoriasis subtypes. Journal of Allergy and Clinical Immunology 2019, 143(3), 1021-1026.
- Tsakok T, Wilson N, Dand N, Loeff FC, Bloem K, Baudry D, Duckworth M, Pan S, Pushpa-Rajah A, Standing JF, De Vries A, Alsharqi A, Becher G, Murphy R, Wahie S, Wright A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, Burden AD, Rispens T, Stocken D, Smith C. Association of Serum Ustekinumab Levels with Clinical Response in Psoriasis. JAMA Dermatology 2019, 155(11), 1235-1243.
- Dand N, Duckworth M, Baudry D, Russell A, Curtis CJ, Lee SH, Evans I, Mason KJ, Alsharqi A, Becher G, Burden AD, Goodwin RG, McKenna K, Murphy R, Perera GK, Rotarescu R, Wahie S, Wright A, Reynolds NJ, Warren RB, Griffiths CEM, Smith CH, Simpson MA, Barker JN, Benham M, Hussain S, Kirby B, Lawson L, McElhone K, Ormerod A, Owen C, Barnes MR, Di Meglio P, Emsley R, Evans A, Payne K, Stocken D. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. Journal of Allergy and Clinical Immunology 2019, 143(6), 2120-2130.
- Yiu ZZN, Smith CH, Ashcroft DM, Lunt M, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB. Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology 2018, 138(3), 534-541.
- Foulkes AC, Watson DS, Carr DF, Kenny JG, Slidel T, Parslew R, Pirmohamed M, Anders S, Reynolds NJ, Griffiths CEM, Warren RB, Barnes MR. A Framework for Multi-Omic Prediction of Treatment Response to Biologic Therapy for Psoriasis. Journal of Investigative Dermatology 2018, 139(1), 100-107.
- Simpson EL, Bruin-Weller M, Flohr C, Ardern-Jones MR, Barbarot S, Deleuran M, Bieber T, Vestergaard C, Brown SJ, Cork MJ, Drucker AM, Eichenfield LF, Foelster-Holst R, Guttman-Yassky E, Nosbaum A, Reynolds NJ, Silverberg JI, Schmitt J, Seyger MMB, Spuls PI, Stalder J-F, Su JC, Takaoka R, Traidl-Hoffmann C, Thyssen JP, van der Schaft J, Wollenberg A, Irvine AD, Paller AS. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. Journal of the American Academy of Dermatology 2017, 77(4), 623-633.
- Taylor K, Swan DJ, Affleck A, Flohr C, Reynolds NJ. Treatment of moderate-to-severe atopic eczema in adults within the UK: Results of a national survey of dermatologists. British Journal of Dermatology 2017, 176(6), 1617-1623.
- Elias MS, Long HA, Newman CF, Wilson PA, West A, McGill PJ, Wu KC, Donaldson MJ, Reynolds NJ. Proteomic analysis of filaggrin deficiency identifies molecular signatures characteristic of atopic eczema. Journal of Allergy and Clinical Immunology 2017, 140(5), 1299-1309.
- Taylor S, Huang Y, Mallet G, Stathopoulou C, Felizardo TC, Sun MA, Martin EL, Zhu N, Woodward EL, Elias M, Scott J, Reynolds NJ, Paul WE, Fowler DH, Amarnath S. PD-1 regulates KLRG1+ group 2 innate lymphoid cells. Journal of Experimental Medicine 2017, 214(6), 1663-1678.
- Iskandar IYK, Ashcroft DM, Warren RB, Evans I, Mcelhone K, Owen CM, Burden AD, Smith CH, Reynolds NJ, Griffiths CEM. Patterns of biologic therapy use in the management of psoriasis: Cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). British Journal of Dermatology 2017, 177(5), 1297-1307.
- Al-Jefri K, Newbury-Birch D, Muirhead CR, Gilvarry E, Araujo-Soares V, Reynolds NJ, Kaner E, Hampton PJ. High prevalence of alcohol use disorders in patients with inflammatory skin diseases. British Journal of Dermatology 2017, 177(3), 837-844.
- Dand N, Mucha S, Tsoi LC, Mahil SK, Stuart PE, Arnold A, Baurecht H, Burden AD, Duffin KC, Chandran V, Curtis CJ, Das S, Ellinghaus D, Ellinghaus E, Enerback C, Esko T, Gladman DD, Griffiths CEM, Gudjonsson JE, Hoffman P, Homuth G, Huffmeier U, Krueger GG, Laudes M, Lee SH, Lieb W, Lim HW, Lohr S, Mrowietz U, Muller-Nurayid M, Nothen M, Peters A, Rahman P, Reis A, Reynolds NJ, Rodriguez E, Schmidt CO, Spain SL, Strauch K, Tejasvi T, Voorhees JJ, Warren RB, Weichenthal M, Weidinger S, Zawistowski M, Nair RP, Capon F, Smith CH, Trembath RC, Abecasis GR, Elder JT, Franke A, Simpson MA, Barker JN. Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling. Human Molecular Genetics 2017, 26(21), 4301-4313.
- Grantham HJ, Stocken DD, Reynolds NJ. Doxycycline: A first-line treatment for bullous pemphigoid?. The Lancet 2017, 389(10079), 1586-1588.
- Iskandar IYK, Ashcroft DM, Warren RB, Lunt M, Mcelhone K, Smith CH, Reynolds NJ, Griffiths CEM. Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. British Journal of Dermatology 2017, 177(5), 1410-1421.
- Harman KE, Brown D, Exton LS, Groves RW, Hampton PJ, Mohd Mustapa MF, Setterfield JF, Yesudian PD. British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017. British Journal of Dermatology 2017, 177(5), 1170-1201.
- Brass D, Fouweather T, Stocken D, Macdonald C, Wilkinson J, Lloyd JJ, Farr PM, Reynolds NJ, Hampton PJ. An observer blinded randomised controlled pilot trial comparing localised immersion psoralen ultraviolet A (PUVA) with localised narrowband ultraviolet B (NBUVB) for the treatment of palmar hand eczema. British Journal of Dermatology 2017, 179(1), 63-71.
- Reynolds NJ, Sinha A, Elias MS, Meggitt SJ. Translating translation into patient benefit for atopic eczema. British Journal of Dermatology 2016, 175(Suppl. S2), 8-12.
- Warren RB, Weatherhead SC, Smith CH, Exton LS, Mustapa MFM, Kirby B, Yesudian PD. British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. British Journal of Dermatology 2016, 175(1), 23-44.
- Healy E, Brown SJ, Langan SM, Nicholls SG, Shams K, Reynolds NJ, UK TREND. Identification of translational dermatology research priorities in the UK: results of an electronic Delphi exercise. British Journal of Dermatology 2015, 173(5), 1191-1198.
- Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker JNWN, Burden AD, Lunt M, McElhone K, Ormerod AD, Owen CM, Reynolds NJ, Griffiths CEM, BADBIR Study Grp. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology 2015, 135(11), 2632-2640.
- Iskandar I, Ashcroft DM, Warren RB, Yiu ZZN, McElhone K, Lunt M, Barker JNWN, Burden AD, Ormerod AD, Reynolds NJ, Smith CH, Griffiths CEM. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. British Journal of Dermatology 2015, 173(2), 510-518.
- Weidmann A, Foulkes AC, Kirkham N, Reynolds NJ. Methotrexate toxicity during treatment of chronic plaque psoriasis: A case report and review of the literature. Dermatology and Therapy 2014, 4(2), 145-156.
- Forrester AR, Elias MS, Woodward EL, Graham M, Williams FM, Reynolds NJ. Induction of a chloracne phenotype in an epidermal equivalent model by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is dependent on aryl hydrocarbon receptor activation and is not reproduced by aryl hydrocarbon receptor knock down. Journal of Dermatological Science 2014, 73(1), 10-22.
- Coates LC, Walsh J, Haroon M, Fitzgerald O, Aslam T, Al-Balushi F, Burden AD, Burden-Teh E, Caperon AR, Cerio R, Chattopadhyay C, Chinoy H, Goodfield MJ, Kay L, Kelly S, Kirkham BW, Lovell CR, Marzo-Ortega H, McHugh N, Murphy R, Reynolds NJ, Smith CH, Stewart EJ, Warren RB, Waxman R, Wilson HE, Helliwell PS. Development and Testing of New Candidate Psoriatic Arthritis Screening Questionnaires Combining Optimal Questions from Existing tools. Arthritis Care and Research 2014, 66(9), 1410-1416.
- Fullard N, Moles A, O'Reilly S, van Laar JM, Faini D, Diboll J, Reynolds NJ, Mann DA, Reichelt J, Oakley F. The c-Rel Subunit of NF-κB Regulates Epidermal Homeostasis and Promotes Skin Fibrosis in Mice. American Journal of Pathology 2013, 182(6), 2109-2120.
- Thomas KS, Crook AM, Nunn AJ, Foster KA, Mason JM, Chalmers JR, Nasr IS, Brindle RJ, English J, Meredith SK, Reynolds NJ, de Berker D, Mortimer PS, Williams HC. Penicillin to Prevent Recurrent Leg Cellulitis. New England Journal of Medicine 2013, 368(18), 1695-1703.
- Jans R, Mottram L, Johnson DL, Brown AM, Sikkink S, Ross K, Reynolds NJ. Lysophosphatidic Acid Promotes Cell Migration through STIM1- and Orai1-Mediated Ca2+i Mobilization and NFAT2 Activation. Journal of Investigative Dermatology 2013, 133(3), 793-802.
- Saunders SP, Goh CSM, Brown SJ, Palmer CNA, Porter RM, Cole C, Campbell LE, Gierlinski M, Barton GJ, Schneider G, Balmain A, Prescott AR, Weidinger S, Baurecht H, Kabesch M, Gieger C, Lee YA, Tavendale R, Mukhopadhyay S, Turner SW, Madhok VB, Sullivan FM, Relton C, Burn J, Meggitt S, Smith CH, Allen MA, Barker JNWN, Reynolds NJ, Cordell HJ, Irvine AD, McLean WHI, Sandilands A, Fallon PG. Tmem79/Matt is the matted mouse gene and is a predisposing gene for atopic dermatitis in human subjects. Journal of Allergy and Clinical Immunology 2013, 132(5), 1121-1129.
- Burden AD, Warren RB, Kleyn CE, McElhone K, Smith CH, Reynolds NJ, Ormerod AD, Griffiths CEM, BADBIR Study Grp. The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives. British Journal of Dermatology 2012, 166(3), 545-554.
- Hampton PJ, Jans R, Flockhart R, Parker G, Reynolds NJ. Lithium regulates keratinocyte proliferation via glycogen synthase kinase 3 and NFAT2 (nuclear factor of activated T cells 2). Journal of Cellular Physiology 2012, 227(4), 1529-1537.
- Fearon P, Lonsdale-Eccles AA, Ross OK, Todd C, Sinha A, Allain F, Reynolds NJ. Keratinocyte secretion of cyclophilin B via the constitutive pathway is regulated through its cyclosporin-binding site. Journal of Investigative Dermatology 2011, 131(5), 1085-1094.
- Weatherhead SC, Farr PM, Jamieson D, Hallinan JS, Lloyd JL, Wipat A, Reynolds NJ. Keratinocyte Apoptosis in Epidermal Remodeling and Clearance of Psoriasis Induced by UV Radiation. Journal of Investigative Dermatology 2011, 131(9), 1916-1926.
- Wahie S, Daly AK, Cordell HJ, Goodfield MJ, Jones SK, Lovell CR, Carmichael AJ, Carr MM, Drummond A, Natarajan S, Smith CH, Reynolds NJ, Meggitt SJ. Clinical and Pharmacogenetic Influences on Response to Hydroxychloroquine in Discoid Lupus Erythematosus: A Retrospective Cohort Study. Journal of Investigative Dermatology 2011, 131(10), 1981-1986.
- Meggitt SJ, Anstey AV, Mustapa MFM, Reynolds NJ, Wakelin S. British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011. British Journal of Dermatology 2011, 165(4), 711-734.
- Flockhart RJ, Armstrong JL, Reynolds NJ, Lovat PE. NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma. British Journal of Cancer 2009, 101(8), 1448-1455.
- Brown SJ, Relton CL, Liao H, Zhao Y, Sandilands A, McLean WH, Cordell HJ, Reynolds NJ. Filaggrin haploinsufficiency is highly penetrant and is associated with increased severity of eczema: further delineation of the skin phenotype in a prospective epidemiological study of 792 school children. British Journal of Dermatology 2009, 161(4), 884-889.
- Smith CH, Anstey AV, Barker JNWN, Burden AD, Chalmers RJG, Chandler DA, Finlay AY, Griffiths CEM, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD, Chair Guideline Grp. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. British Journal of Dermatology 2009, 161(5), 987-1019.
- Flockhart R, Diffey BL, Farr PM, Lloyd JJ, Reynolds NJ. NFAT regulates induction of COX-2 and apoptosis of keratinocytes in response to ultravioloet radiation exposure. FASEB Journal 2008, 22(12), 4218-4227.
- Brown SJ, Relton CL, Liao H, Zhao Y, Sandilands A, Wilson IJ, Burn J, Reynolds NJ, McLean WH, Cordell HJ. Filaggrin null mutations and childhood atopic eczema: A population-based case-control study. Journal of Allergy and Clinical Immunology 2008, 121(4), 940-946.
- Weatherhead S, Robson SC, Reynolds NJ. Pregnancy plus - Management of psoriasis in pregnancy. British Medical Journal 2007, 334(7605), 1218-1220B.
- Weatherhead S, Robson SC, Reynolds NJ. Pregnancy plus - Eczema in pregnancy. British Medical Journal 2007, 335(7611), 152-154.
- Barker JNWN, Palmer CNA, Zhao Y, Liao H, Hull PR, Lee SP, Allen MH, Meggitt SJ, Reynolds NJ, Trembath RC, McLean WHI. Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood. Journal of Investigative Dermatology 2007, 127(3), 564-567.
- Hampton PJ, Ross OK, Reynolds NJ. Increased nuclear β-catenin in suprabasal involved psoriatic epidermis. British Journal of Dermatology 2007, 157(6), 1168-1177.
- Weatherhead S, Wahie S, Reynolds NJ, Meggitt SJ. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. British Journal of Dermatology 2007, 156(2), 346-351.
- Ross K, Whitaker M, Reynolds NJ. Agonist-induced calcium entry correlates with STIM1 translocation. Journal of Cellular Physiology 2007, 211(3), 569-576.
- Ekelund E, Saaf A, Tengvall-Linder M, Melen E, Link J, Barker J, Reynolds NJ, Meggitt SJ, Kere J, Wahlgren C-F, Pershagen G, Wickman M, Nordenskjold M, Kockum I, Bradley M. Elevated expression and genetic association links the SOCS3 gene to atopic dermatitis. American Journal of Human Genetics 2006, 78(6), 1060-1065.
- Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: A double-blind, randomised controlled trial. The Lancet 2006, 367(9513), 839-846.
- McGill A, Frank A, Emmett N, Turnbull DM, Birch-Machin MA, Reynolds NJ. The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria. FASEB Journal 2005, 19(8), 1012-1014.
- Smith CH, Anstey AV, Barker JNWN, Burden AD, Chalmers RJG, Chandler D, Finlay AY, Grifitths CEM, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. British Journal of Dermatology 2005, 153(3), 486-497.
- McBride SR, Walker P, Reynolds NJ. Optimising the frequency of outpatient short contact dithranol treatment: a randomised, within patient controlled trial. British Journal of Dermatology 2003, 149(6), 1259-1265.
- Al-Daraji WI, Grant KR, Ryan K, Saxton A, Reynolds NJ. Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A. Journal of Investigative Dermatology 2002, 118(5), 779-788.
- Reynolds NJ, Franklin V, Gray JC, Diffey BL, Farr PM. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: A randomised controlled trial. Lancet 2001, 357(9273), 2012-2016.
- Todd C, Reynolds NJ. Up-regulation of p21(WAF1) by phorbol ester and calcium in human keratinocytes through a protein kinase C-dependent pathway. American Journal of Pathology 1998, 153(1), 39-45.
-
Conference Proceedings (inc. Abstracts)
- Calero-Diaz H, Hamad RA, Atallah C, Casement J, Canoy D, Reynolds NJ, Barnes M, Missier P. Interpretable and robust hospital readmission predictions from Electronic Health Records. In: IEEE International Conference on Big Data (BigData 2023). 2023, Sorrento, Italy: IEEE.
- Reynolds NJ, Sinha A, Lonsdale-Eccles A, Fearon P, Forrester A, Elias MS, Todd C, Allain F. Role of cyclophilin B in regulating human keratinocyte differentiation, growth and homeostasis and in mediating the therapeutic effects of ciclosporin in atopic eczema. In: British Skin Foundation, Skin Deep - 20 Years of Research, 20th Anniversary Conference. 2016, London, U.K: Wiley-Blackwell Publishing Ltd.
- Elias M, Long H, Brown S, Donaldson M, Reynolds N. Methotrexate regulates late epidermal differentiation and barrier function in normal and filaggrin-deficient models and in atopic eczema in vivo. In: BSID Annual Meeting. 2016, Dundee: Wiley-Blackwell Publishing Ltd.
- Hampton P, Al-Jefri K, Muirhead C, Newbury-Birch D, Kaner K, Gilvarry E, Araujo-Soares V, Reynolds N. Examining the prevalence of alcohol use disorders in patients with skin disease. In: British Skin Foundation, Skin Deep - 20 Years of Research, 20th Anniversary Conference. 2016, London: Wiley-Blackwell Publishing Ltd.
- Wu K, Morse M, Donaldson M, Reynolds N. Inhibition of bromodomain extraterminal proteins differentially regulates cytokine production in an in vitro skin inflammation model relevant to psoriasis. In: British Society for Investigative Dermatology Annual Meeting 2015. 2015, Southampton, UK: Wiley-Blackwell.
- Mottram L, Begg M, Reynolds N. The role of store-operated calcium entry in epidermal wound healing responses. In: British Society of Investigative Dermatology Annual Meeting. 2014, Newcastle upon Tyne, UK: Wiley-Blackwell.
-
Editorials
- Grantham HJ, Reynolds NJ. The devil is in the data: differences in drug persistence between SNIIRAM, the French national health insurance database, and psoriasis biologics intervention registers. British Journal of Dermatology 2019, 180(1), 8-10.
- Wu KCP, Reynolds NJ. CARD14 mutations may predict response to antitumour necrosis factor-α therapy in psoriasis: a potential further step towards personalized medicine. British Journal of Dermatology 2016, 175(1), 17-18.
- Anstey A, Reynolds NJ. What does the BJD now stand for? A position statement. British Journal of Dermatology 2015, 172(6), 1463-1465.
- Griffiths CEM, Barnes MR, Burden AD, Nestle FO, Reynolds NJ, Smith CH, Warren RB, Barker JNWN, PSORT Consortium. Establishing an Academic-Industrial Stratified Medicine Consortium: Psoriasis Stratification to Optimize Relevant Therapy. Journal of Investigative Dermatology 2015, 135(12), 2903-2907.
- Reynolds NJ. One hundred and twenty-five years and counting: into an era of systems dermatology. British Journal of Dermatology 2014, 171(6), 1279-1281.
- Wu KCP, Reynolds NJ. Predicting response to anti-interleukin 12/23 treatment in psoriasis. British Journal of Dermatology 2013, 169(2), 240-241.
- Wu K, Reynolds NJ. Pharmacogenetic screening to prevent carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome: a critical appraisal. British Journal of Dermatology 2012, 166(1), 7-11.
- Hampton PJ, Reynolds NJ. Calcineurin inhibitors for the treatment of skin disease: How do they work?. Clinical and Experimental Allergy 2005, 35(5), 549-550.
-
Letters
- Hussain AB, Havelin A, Ball S, Weatherhead S, Reynolds NJ, Hampton P. Increasing to weekly adalimumab dosing leads to improved psoriasis outcomes—A retrospective single-centre review of real-world data. Journal of the European Academy of Dermatology and Venereology 2023, 37(4), e527-e528.
- Mason KJ, Burden AD, Barker JNWN, Lunt M, Ali H, Kleyn CE, McElhone K, Soliman MM, Green AC, Griffiths CEM, Reynolds NJ, Ormerod AD, Benham M, Browne F, Evans I, Hussain S, Kirby B, Lawson L, Laws P, Mackenzie T, McPherson T, Murphy R, Owen C, Pearson E, Richards J, Smith C, Warren R. Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non-biologic systemic therapies. Journal of the European Academy of Dermatology and Venereology 2021, 35(8), e496-e498.
- Abuabara K, Nicholls SG, Langan SM, Guttman-Yassky E, Reynolds NJ, Paller AS, Brown SJ, the International Eczema Council Priority Research Group. Priority research questions in atopic dermatitis: an International Eczema Council eDelphi consensus. British Journal of Dermatology 2021, 185(1), 203-205.
- Simpson EL, Reynolds NJ, Flohr C, Paller AS, Silverberg JI, Cork MJ, Guttman-Yassky E, Irvine AD. Response to “Comment on: ‘When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council’”. Journal of the American Academy of Dermatology 2018, 79(2), e25-e26.
- Coates LC, Aslam T, Al-Balushi F, Burden AD, Burden-The E, Caperon AR, Cerio R, Chattopadhyay C, Chinoy H, Goodfield MJ, Kay L, Kelly S, Kirkham BW, Lovell CR, Marzo-Ortega H, McHugh N, Murphy R, Reynolds NJ, Smith CH, Stewart EJ, Warren RB, Waxman R, Wilson HE, Helliwell PS. Psoriatic arthritis screening tools: Study design and methodologic challenges - reply from authors. British Journal of Dermatology 2014, 170(4), 995-996.
- Wahie S, McColl E, Reynolds NJ, Meggitt SJ. Measuring disease activity and damage in cutaneous lupus erythematosus. British Journal of Dermatology 2011, 164(1), 221-222.
- Brown SJ, Sandilands A, Zhao Y, Liao H, Relton CL, Meggitt SJ, Trembath RC, Barker JNWN, Reynolds NJ, Cordell HJ, McLean WHI. Prevalent and low-frequency null mutations in the filaggrin gene are associated with early-onset and persistent atopic eczema. Journal of Investigative Dermatology 2008, 128(6), 1591-1594.
- Veal CD, Reynolds NJ, Meggitt SJ, Allen MH, Lindgren CM, Kere J, Trembath RC, Barker JNWN. Absence of association between asthma and high serum immunoglobulin E associated GPRA haplotypes and adult atopic dermatitis [8]. Journal of Investigative Dermatology 2005, 125(2), 399-401.
-
Notes
- Grantham HJ, Hussain AB, Reynolds NJ. Serum S100A8/A9 May Act as Biomarker of Atherosclerosis Severity in Psoriasis. Journal of Investigative Dermatology 2022, 142(11), 2848-2850.
- Yiu ZZN, Barker JNWN, Barnes MR, Di Meglio P, Emsley R, Reynolds NJ, Smith CH, Warren RB, Griffiths CEM. Meeting Report: Psoriasis Stratification to Optimise Relevant Therapy Showcase. Journal of Investigative Dermatology 2021, 141(8), 1872-1878.
- Reynolds NJ, Enk AH. The History and Future Prospects of ISID: A European Perspective. Journal of Investigative Dermatology 2020, 140(9), S178-S180.
- Gardner LCS, Grantham HJ, Reynolds NJ. IL-17 May Be a Key Cytokine Linking Psoriasis and Hyperglycemia. Journal of Investigative Dermatology 2019, 139(6), 1214-1216.
- Samuel RJ, Reynolds NJ. Ustekinumab for severe atopic dermatitis: an important negative study. British Journal of Dermatology 2017, 177(2), 339-341.
- Jabbar-Lopez ZK, Weatherhead SC, Reynolds NJ. Kidney disease in moderate-to-severe psoriasis: A critical appraisal. British Journal of Dermatology 2016, 174(2), 267-270.
-
Reviews
- Esson GA, Hussain AB, Meggitt SJ, Reynolds NJ, Sayer JA. Cutaneous manifestations of acute kidney injury. Clinical Kidney Journal 2022, 15(5), 855-864.
- Cro S, Patel P, Barker J, Burden DA, Griffiths CEM, Lachmann HJ, Reynolds NJ, Warren RB, Capon F, Smith C, Cornelius V. A randomised placebo controlled trial of anakinra for treating pustular psoriasis: Statistical analysis plan for stage two of the APRICOT trial. Trials 2020, 21(1), 158.
- Blakeway H, Van-de-Velde V, Allen VB, Kravvas G, Palla L, Page MJ, Flohr C, Weller RB, Irvine AD, McPherson T, Roberts A, Williams HC, Reynolds N, Brown SJ, Paternoster L, Langan SM. What is the evidence for interactions between filaggrin null mutations and environmental exposures in the aetiology of atopic dermatitis? A systematic review. British Journal of Dermatology 2019, 183(3), 443-451.
- Hussain AB, Samuel R, Hegade VS, Jones DE, Reynolds NJ. Pruritus secondary to primary biliary cholangitis: a review of the pathophysiology and management with phototherapy. British Journal of Dermatology 2019, 181(6), 1138-1145.
- Mason KJ, Williams S, Yiu ZZN, McElhone K, Ashcroft DM, Kleyn CE, Jabbar-Lopez ZK, Owen CM, Reynolds NJ, Smith CH, Wilson N, Warren RB, Griffiths CEM. Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. British Journal of Dermatology 2019, 181(2), 256-264.
- Jabbar-Lopez ZK, Wu KC, Reynolds NJ. Newer agents for psoriasis in adults. BMJ 2014, 349, g4026.
- Weatherhead SC, Farr PM, Reynolds NJ. Spectral effects of UV on psoriasis. Photochemical & Photobiological Sciences 2013, 12(1), 47-53.
- Brown S, Reynolds NJ. Atopic and non-atopic eczema. British Medical Journal 2006, 332(7541), 584-588.
- Meggitt SJ, Reynolds NJ. Azathioprine for atopic dermatitis. Clinical and Experimental Dermatology 2001, 26(5), 369-375.